Analyst rates Boston Scientific a Hold: EP and WATCHMAN sales fell 5.3% and 5.9% in Q3, and recovery remains uncertain with 2027 expected to be the trough.
Detailed price information for Coreweave Cl A (CRWV-Q) from The Globe and Mail including charting and trades.
BSX bets on WATCHMAN growth through clinical trials and physician outreach, even as slowing demand and rising competition cloud its outlook.
Investing.com -- S&P Global Ratings has revised its outlook on Boston Scientific Corp. to negative from stable, warning that deepening commercial headwinds across its core product franchises will likely keep financial leverage stretched through 2028. While the rating agency affirmed the medical device maker’s ’A-’ issuer credit rating and senior unsecured debt rating, S&P highlighted that deteriorating top-line momentum coincides with the balance-sheet burden of its pending $14.5 billion acquisi
Detailed price information for Johnson & Johnson (JNJ-N) from The Globe and Mail including charting and trades.
RevMedica, an innovative medical technology company developing intelligent surgical stapling solutions, today announced the appointment of Mike Jones as Chief Executive Officer and a member of its Board of Directors. Jones succeeds RevMedica founder Tom Wenchell, who will transition to President and Chief Operating Officer, continuing to lead product development, technical operations, and day-to-day business execution.
Detailed price information for Medtronic Inc (MDT-N) from The Globe and Mail including charting and trades.
Detailed price information for Medtronic Inc (MDT-N) from The Globe and Mail including charting and trades.
Tipranks Press Release.
Detailed price information for Boston Scientific Corp (BSX-N) from The Globe and Mail including charting and trades.
Detailed price information for Boston Scientific Corp (BSX-N) from The Globe and Mail including charting and trades.
CAMBRIDGE, Mass., November 02, 2026--Blackstone Life Sciences ("BXLS") today announced a $455 million collaboration with Boston Scientific Corporation (NYSE: BSX) to co-fund the development of the VITALYST™ Temporary Percutaneous Transvalvular Circulatory Support System program. The VITALYST system is a next-generation, miniature heart pump intended to increase cardiac output and improve blood flow from the heart to the brain and other vital organs. It is designed to treat acute myocardial infar
Detailed price information for Boston Scientific Corp (BSX-N) from The Globe and Mail including charting and trades.
Detailed price information for Boston Scientific Corp (BSX-N) from The Globe and Mail including charting and trades.
Detailed price information for Boston Scientific Corp (BSX-N) from The Globe and Mail including charting and trades.
Detailed price information for Boston Scientific Corp (BSX-N) from The Globe and Mail including charting and trades.
Boston Scientific (BSX) moved into focus after third quarter 2026 results, as modest sales of US$5.14b and net income of US$582m met a sharply lower market reaction and fresh earnings guidance. The sharp 1-day share price decline of 5.84% brings Boston Scientific to US$42.43, capping a weak run in which the share price return is down 7.76% over 90 days and the 1-year total shareholder return has fallen 57.70%. This suggests sentiment has faded as investors reassess risk after the cyberattack,...
This is the newest page. Registered accounts read further back.